About the study

The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

Inclusion CriteriaErythematosus

1. Patients who have a diagnosis of pediatric or adult SLE according to the ACR 1997 revised criteria for ≥ 24 weeks prior to signing the ICF
2. To be eligible a patient must have SLEDAI-2K ≥ 6 points and "Clinical" SLEDAI-2K score ≥4 points at screening
3. BILAG2004 with at least 1 of the following:
4. BILAG2004 level A disease in ≥ 1 organ system
5. BILAG2004 level B disease in ≥ 2 organ systems
6. Physician's Global Assessment (PGA) score ≥ 1.0 on a 0 to 3 VAS at Screening
7. Antinuclear antibody, and/or Anti-dsDNA and/oranti-Smith positive at Screening,
8. Must be on stable background standard therapy with DMARD, glucocorticoids or anti-malarials alone or in combinations.

Exclusion criteria

1. Active severe or unstable neuropsychiatric SLE
2. Active severe SLE-driven renal disease
3. History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to signing the ICF.
4. History of recurrent infection requiring hospitalization and IV antibiotics (eg, 3 or more of the same type of infection over the previous 52 weeks).
5. Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the patient to infection, or a positive result for human immunodeficiency virus (HIV) infection confirmed by central laboratory at Screening.
6. At Screening, confirmed positive test for hepatitis B serology and positive test for hepatitis C antibody
7. Any severe case herpes zoster infection at any time prior to Week 0 (Day 1),
8. Opportunistic infection requiring hospitalization or IV antimicrobial treatment within 3 years of randomization.
9. History of cancer, apart from:
10. Squamous or basal cell carcinoma of the skin treated with documented success of curative therapy ≥ 3 months prior to Week 0 (Day 1)
11. Cervical cancer in situ treated with apparent success with curative therapy ≥ 1 year prior to Week 0 (Day 1).

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.